Leaflet: information for the user
Genvoya 150mg/150mg/200mg/10mg film-coated tablets
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of the leaflet includes information on how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack and other information
If Genvoya has been prescribed to your child, please note that all the information in this leaflet that refers to ‘you’ also applies to your child (in this case, when you read ‘you’, replace it with ‘your child’).
Genvoya contains four active substances:
Genvoya is a single tablet for the treatment of human immunodeficiency virus (HIV)-1 infectionin adults, adolescents and children from 6 years of age or older, weighing at least 25 kg.
Genvoya reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of developing diseases associated with HIV infection.
Do not take Genvoya:
?If you are in any of these situations, do not take Genvoya and consult your doctor immediately.
Warnings and precautions
You must remain under the supervision of your doctor while taking Genvoya.
While taking this medicine, you can still transmit HIV to others, even if effective antiviral treatment reduces the risk. Consult your doctor about the precautions needed to avoid infecting others. This medicine is not a cure for HIV infection. While you are taking Genvoya, you may still experience infections or other diseases associated with HIV infection.
Consult your doctor before starting Genvoya:
If you have hepatitis B infection, liver problems may worsen after stopping Genvoya. It is important that you do not stop taking Genvoya without first talking to your doctor: see section 3, Do not stop taking Genvoya.
While taking Genvoya
Once you start taking Genvoya, be aware of:
?If you notice any of these symptoms, tell your doctor immediately.For more information, see section 4, Possible side effects.
Children and adolescents
Do not give this medicine to childrenunder 6 years of age or weighing less than 25 kg, regardless of age. The use of Genvoya in children under 6 years of age has not been studied.
Other medicines and Genvoya
Tell your doctor or pharmacistif you are taking, have recently taken or might take any other medicines. Genvoya may interact with other medicines. As a result, the levels of Genvoya or other medicines in your blood may be affected. This may stop your medicines from working properly or may increase your risk of side effects. In some cases, your doctor may need to adjust the dose or monitor your blood levels.
Medicines that must not be taken with Genvoya:
?If you are taking any of these medicines, do not take Genvoya and tell your doctor immediately.
Medicines used to treat hepatitis B virus infection:
Do not take Genvoya with medicines that contain:
?Consult your doctorif you are taking any of these medicines.
Other types of medicines:
Tell your doctor if you are taking:
These medicines are used to treat allergies, asthma, inflammatory bowel disease, inflammatory eye, joint and muscle conditions, and other inflammatory conditions. If alternatives cannot be used, they should only be used after a clinical evaluation and with close monitoring by your doctor to assess the adverse effects of corticosteroids.
?Tell your doctor if you are taking these or other medicines.Do not stop your treatment without consulting your doctor.
?If you are taking an antacid or a multivitamin supplement, take it at least 4 hours before or at least 4 hours after Genvoya.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Genvoya may cause dizziness. If you feel dizzy while taking Genvoya, do not drive, ride a bicycle or use tools or machines.
Genvoya contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
?If you are in any of these situations, consult your doctor before starting Genvoya.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
The recommended dose is:
Adults:one tablet once daily with food
Adolescents and children from 6 years of age or older, weighing at least 25 kg:one tablet once daily with food
Do not chew or crush the tablet.
If you have difficulty swallowing the tablet whole, you can split it into two halves. Swallow the two halves of the tablet one after the other to take the full dose. Do not store the split tablet.
Always take the dose recommended by your doctor.This is to ensure that your medicine is fully effective and to reduce the risk of developing resistance to treatment. Do not change the dose unless your doctor tells you to.
Do not take antacids or multivitamin supplements at the same time as Genvoya.If you are taking an antacid like aluminium/magnesium hydroxide or a multivitamin supplement, take it at least 4 hours before or at least 4 hours after Genvoya.
If you are on dialysis, take your daily dose of Genvoya after dialysis is completed.
If you take more Genvoya than you should
If you accidentally take more than the recommended dose of Genvoya, you may be at greater risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Consult your doctor immediately or go to the emergency department at your nearest hospital. Take the pack of tablets with you so that you can easily describe what you have taken.
If you forget to take Genvoya
It is important that you do not miss a dose of Genvoya.
If you miss a dose:
If you vomit within 1 hour of taking Genvoya, take another tablet with food.
Do not stop taking Genvoya
Do not stop taking Genvoya without talking to your doctor first.Stopping Genvoya may seriously affect your response to future treatments. If Genvoya is stopped for any reason, consult your doctor before restarting Genvoya tablets.
When you have almost finished a pack of Genvoya, go to your doctor or pharmacist to get more. This is very important, as the amount of virus may start to increase if the medicine is stopped, even for a short time. This may make the disease more difficult to treat.
If you have both HIV and hepatitis B, it is especially important not to stop your treatment with Genvoya without first talking to your doctor. You may need to have blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, it is not recommended to stop treatment as this may cause worsening of your hepatitis, which can be life-threatening.
?Talk to your doctor immediatelyabout new or unusual symptoms after stopping treatment, especially symptoms that you think may be related to hepatitis B virus infection.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This is partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can produce adverse effects, although not all people suffer from them. When treating HIV infection, it is not always possible to distinguish if some of the unwanted effects are due to Genvoya or to other medications being taken at the same time or to the disease caused by HIV itself.
Possible Serious Adverse Effects: Inform a Doctor Immediately
If you notice any of the above adverse effects, inform your doctor immediately.
Very Common Adverse Effects
(may affect more than 1 in 10 people)
Common Adverse Effects
(may affect up to 1 in 10 people)
Uncommon Adverse Effects
(may affect up to 1 in 100 people)
If you consider any of the adverse effects you are experiencing to be serious, inform your doctor.
Other Effects that May be Observed During HIV Treatment
The frequency of the following adverse effects is not known (the frequency cannot be estimated from the available data).
If you notice any of these symptoms, inform your doctor.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the carton and blister after {CAD}. The expiration date is the last day of the month indicated.
Store in the original packaging to protect from moisture. Keep the bottle tightly closed.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Genvoya Composition
The active ingredients areelvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Each Genvoya film-coated tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.
The other ingredients are
Tablet core:
Lactose (in the form of monohydrate), microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, silicon dioxide, sodium lauryl sulfate, magnesium stearate.
Film coating:
Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), aluminum lake indigo carmine (E132), yellow iron oxide (E172).
Appearance and Package Contents
Genvoya film-coated tablets are green, capsule-shaped tablets marked with "GSI" on one side and "510" on the other. Genvoya is available in bottles of 30 tablets (with a silica gel desiccant that should be kept in the bottle to help protect the tablets). The silica gel desiccant is contained in a separate pouch or container and should not be swallowed.
This medication is available in packages of 1 bottle of 30 film-coated tablets and in packages of 90 (3 bottles of 30) film-coated tablets. Not all package sizes may be marketed.
Marketing Authorization Holder
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Gilead Sciences Belgium SPRL-BVBA Tel: +32 (0) 24 01 35 50 | Lithuania Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 |
Greece Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888 | Luxembourg Gilead Sciences Belgium SPRL-BVBA Tel: +32 (0) 24 01 35 50 |
Czech Republic Gilead Sciences s.r.o. Tel: +420 910 871 986 | Hungary Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888 |
Denmark Gilead Sciences Sweden AB Tel: +46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888 |
Germany Gilead Sciences GmbH Tel: +49 (0) 89 899890-0 | Netherlands Gilead Sciences Netherlands B.V. Tel: +31 (0) 20 718 36 98 |
Estonia Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 | Norway Gilead Sciences Sweden AB Tel: +46 (0) 8 5057 1849 |
Greece Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: +30 210 8930 100 | Austria Gilead Sciences GesmbH Tel: +43 1 260 830 |
Spain Gilead Sciences, S.L. Tel: +34 91 378 98 30 | Poland Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 |
France Gilead Sciences Tel: +33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: +351 21 7928790 |
Croatia Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888 | Romania Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: +353 (0) 214 825 999 | Slovenia Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888 |
Iceland Gilead Sciences Sweden AB Tel: +46 (0) 8 5057 1849 | Slovakia Gilead Sciences Slovakia s.r.o. Tel: +421 232 121 210 |
Italy Gilead Sciences S.r.l. Tel: +39 02 439201 | Finland Gilead Sciences Sweden AB Tel: +46 (0) 8 5057 1849 |
Cyprus Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: +30 210 8930 100 | Sweden Gilead Sciences Sweden AB Tel: +46 (0) 8 5057 1849 |
Latvia Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: +44 (0) 8000 113 700 |
Date of Last Revision of this Leaflet:<{MM/AAAA}> <{month AAAA}>.
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.